|
|
||||||||
Departments of Medicine, Harvard Medical School and the Robert B. Brigham and Peter Bent Brigham Hospitals, Boston, Massachusetts
Abstract
The C3b inactivator (C3bINA) contained in whole human serum has been purified by sequential diethylaminoethyl- and carboxymethyl-cellulose chromatography and polyacrylamide disc gel electrophoresis to yield a material which produces antibody to C3bINA when used to immunize rabbits. The specificity of the antibody for C3bINA was established by its ability to neutralize C3bINA activity in free solution. On Ouchterlony analysis against normal plasma, this anti-C3bINA gives a line of complete identity with antibody to conglutinogen activating factor (KAF) and a reaction of complete non-identity with antibody to
-2-glycoprotein II, the protein which has been found by others to be the C3 proactivator of the alternate pathway for activation of the late complement components.
Footnotes
1 Supported by Grants AI-07722 and AM-12051 from the National Institutes of Health, a grant from the John A. Hartford Foundation, Inc., and a grant from the Massachusetts Chapter, The Arthritis Foundation.
2 Investigator, Howard Hughes Medical Institute.
3 Lieutenant Commander, United States Navy.
This article has been cited by other articles:
![]() |
W. Chapman and P. Ward Babesia rodhaini: requirement of complement for penetration of human erythrocytes Science, April 1, 1977; 196(4285): 67 - 70. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |